<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519597</url>
  </required_header>
  <id_info>
    <org_study_id>VGSKAS-4731</org_study_id>
    <nct_id>NCT00519597</nct_id>
  </id_info>
  <brief_title>Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea</brief_title>
  <acronym>RICCADSA</acronym>
  <official_title>Randomized Intervention With CPAP in Coronary Artery Disease and Sleep Apnea - RICCADSA Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Skaraborg Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Heart Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Foundation of Karnsjukhuset Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ResMed Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Skaraborg Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea (OSA) worsens the prognosis in patients with coronary artery disease
      (CAD). Many of these subjects do not report daytime sleepiness, and therefore, are not
      considered for OSA treatment with continuous positive airway pressure (CPAP). There is lack
      of evidence regarding the impact of CPAP on the long-term prognosis of CAD patients with OSA.
      The Randomized Intervention with CPAP in CAD and OSA (RICCADSA) trial is designed to address
      if CPAP treatment reduces the combined rate of new revascularization, myocardial infarction,
      stroke and cardiovascular mortality over mean follow-up period of 3-years in CAD patients
      with OSA without daytime sleepiness.Secondary outcomes include cardiovascular biomarkers,
      cardiac function, maximal exercise capacity and quality of life at baseline, 3-month- and
      1-year follow-up as well as polysomnographic findings and adherence to CPAP therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: OSA is a common condition in CAD with a poor prognosis.Many of these subjects do
      not report daytime sleepiness, and therefore, are not considered for OSA treatment with CPAP.
      There is lack of evidence regarding the impact of CPAP on the long-term prognosis of CAD
      patients with OSA.

      Objective: The RICCADSA trial is designed to address if CPAP treatment reduces the combined
      rate of new revascularization, myocardial infarction, stroke and cardiovascular mortality
      over a mean follow-up period of 3-years in CAD patients with OSA (Apnea-Hypopnea-Index
      [AHI]&gt;=15 per h) without daytime sleepiness (Epworth Sleepiness Scale [ESS]&lt;10). Secondary
      outcomes include cardiovascular biomarkers, cardiac function, maximal exercise capacity and
      quality of life at baseline, 3-month- and 1-year follow-up as well as polysomnographic
      findings and adherence to CPAP therapy.

      Patients and Methods: A sample of 511 CAD patients (122 non-sleepy OSA patients randomized to
      CPAP, 122 to non-CPAP; 155 sleepy OSA patients [ESS&gt;=10] on CPAP, and 112 CAD patients
      without OSA [AHI &lt;5 per h]) were included. The trial has 80% power to detect a risk reduction
      from an assumed composite end-point rate of 25% to 12% for the primary outcome at
      intention-to-treat basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The combined rate of cardiovascular mortality, stroke, myocardial infarction and the need for a new revascularization.</measure>
    <time_frame>Three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular biomarkers, left ventricular function, maximal exercise capacity, quality of life, anxiety and depression state.</measure>
    <time_frame>Three months and one year, respectively.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asymptomatic OSA (CPAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Asymptomatic OSA (no CPAP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Symptomatic OSA (OSAS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-OSA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ResMed S8 (Auto-CPAP)</intervention_name>
    <description>AutoCPAP during sleep</description>
    <arm_group_label>I</arm_group_label>
    <arm_group_label>III</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with angiographically-verified CAD who have newly undergone PCI or CABG
             treatment

          -  Written, informed study consent

          -  OSA (AHI&gt;=15 per hour) or non-OSA (AHI&lt;5 per hour) diagnosis on the unattended sleep
             recording at home

        Exclusion Criteria:

          -  Patients with already treated OSAS

          -  Patients presenting mainly central apneas (Cheynes-Stokes breathing)

          -  Patients with borderline OSA (AHI &lt;15 and &gt;=5 per hour) upon the unattended sleep
             recording at home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yüksel Peker, Ass. Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Göteborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skövde</city>
        <zip>54185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Baniak LM, Chasens ER, Luyster FS, Strollo PJ Jr, Thunström E, Peker Y. Obstructive sleep apnea and self-reported functional impairment in revascularized patients with coronary artery disease in the RICCADSA trial. Sleep Breath. 2018 Dec;22(4):1169-1177. doi: 10.1007/s11325-018-1733-4. Epub 2018 Oct 15.</citation>
    <PMID>30324547</PMID>
  </results_reference>
  <results_reference>
    <citation>Balcan B, Thunström E, Strollo PJ Jr, Peker Y. Continuous Positive Airway Pressure Treatment and Depression in Adults with Coronary Artery Disease and Nonsleepy Obstructive Sleep Apnea. A Secondary Analysis of the RICCADSA Trial. Ann Am Thorac Soc. 2019 Jan;16(1):62-70. doi: 10.1513/AnnalsATS.201803-174OC.</citation>
    <PMID>30130421</PMID>
  </results_reference>
  <results_reference>
    <citation>Luyster FS, Strollo PJ Jr, Thunström E, Peker Y. Long-term use of continuous positive airway pressure therapy in coronary artery disease patients with nonsleepy obstructive sleep apnea. Clin Cardiol. 2017 Dec;40(12):1297-1302. doi: 10.1002/clc.22827. Epub 2017 Dec 14.</citation>
    <PMID>29243273</PMID>
  </results_reference>
  <results_reference>
    <citation>Peker Y, Thunström E, Glantz H, Wegscheider K, Eulenburg C. Outcomes in coronary artery disease patients with sleepy obstructive sleep apnoea on CPAP. Eur Respir J. 2017 Dec 7;50(6). pii: 1700749. doi: 10.1183/13993003.00749-2017. Print 2017 Dec.</citation>
    <PMID>29217597</PMID>
  </results_reference>
  <results_reference>
    <citation>Thunström E, Glantz H, Yucel-Lindberg T, Lindberg K, Saygin M, Peker Y. CPAP Does Not Reduce Inflammatory Biomarkers in Patients With Coronary Artery Disease and Nonsleepy Obstructive Sleep Apnea: A Randomized Controlled Trial. Sleep. 2017 Nov 1;40(11). doi: 10.1093/sleep/zsx157. Erratum in: Sleep. 2019 Feb 1;42(2):.</citation>
    <PMID>29029237</PMID>
  </results_reference>
  <results_reference>
    <citation>Glantz H, Johansson MC, Thunström E, Guron CW, Uzel H, Saygin M, Herlitz J, Peker Y. Effect of CPAP on diastolic function in coronary artery disease patients with nonsleepy obstructive sleep apnea: A randomized controlled trial. Int J Cardiol. 2017 Aug 15;241:12-18. doi: 10.1016/j.ijcard.2017.03.100. Epub 2017 Mar 25.</citation>
    <PMID>28408103</PMID>
  </results_reference>
  <results_reference>
    <citation>Peker Y, Wegscheider K, Eulenburg C. Reply: Effect of Continuous Positive Airway Pressure Therapy on Cardiovascular Outcomes: Risk Assessment. Am J Respir Crit Care Med. 2017 Sep 1;196(5):662-663. doi: 10.1164/rccm.201702-0420LE.</citation>
    <PMID>28296427</PMID>
  </results_reference>
  <results_reference>
    <citation>Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial. Am J Respir Crit Care Med. 2016 Sep 1;194(5):613-20. doi: 10.1164/rccm.201601-0088OC.</citation>
    <PMID>26914592</PMID>
  </results_reference>
  <results_reference>
    <citation>Glantz H, Thunström E, Johansson MC, Wallentin Guron C, Uzel H, Ejdebäck J, Nasic S, Peker Y. Obstructive sleep apnea is independently associated with worse diastolic function in coronary artery disease. Sleep Med. 2015 Jan;16(1):160-7. doi: 10.1016/j.sleep.2014.08.018. Epub 2014 Nov 18.</citation>
    <PMID>25547036</PMID>
  </results_reference>
  <results_reference>
    <citation>Thunström E, Glantz H, Fu M, Yucel-Lindberg T, Petzold M, Lindberg K, Peker Y. Increased inflammatory activity in nonobese patients with coronary artery disease and obstructive sleep apnea. Sleep. 2015 Mar 1;38(3):463-71. doi: 10.5665/sleep.4510.</citation>
    <PMID>25325463</PMID>
  </results_reference>
  <results_reference>
    <citation>Glantz H, Thunström E, Herlitz J, Cederin B, Nasic S, Ejdebäck J, Peker Y. Occurrence and predictors of obstructive sleep apnea in a revascularized coronary artery disease cohort. Ann Am Thorac Soc. 2013 Aug;10(4):350-6. doi: 10.1513/AnnalsATS.201211-106OC.</citation>
    <PMID>23952854</PMID>
  </results_reference>
  <results_reference>
    <citation>Peker Y, Glantz H, Thunström E, Kallryd A, Herlitz J, Ejdebäck J. Rationale and design of the Randomized Intervention with CPAP in Coronary Artery Disease and Sleep Apnoea--RICCADSA trial. Scand Cardiovasc J. 2009 Feb;43(1):24-31. doi: 10.1080/14017430802276106.</citation>
    <PMID>18663661</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>August 20, 2007</study_first_submitted>
  <study_first_submitted_qc>August 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Skaraborg Hospital</investigator_affiliation>
    <investigator_full_name>Yuksel Peker</investigator_full_name>
    <investigator_title>MD, PhD, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Sleep Apnea</keyword>
  <keyword>CPAP</keyword>
  <keyword>Revascularization</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

